FDA TRG Compliance Audit Checklist for Distributors

An FDA Tissue Reference Group (TRG) compliance audit checklist for biologic distributors evaluates whether a vendor's human cells, tissues, and cellular and tissue-based products (HCT/Ps) satisfy 21 CFR Part 1271 regulations for minimal manipulation and homologous use. Medical practice administrators and clinical directors use this checklist to audit distributor documentation, verify donor eligibility screening, ensure proper cold-chain handling, and confirm regulatory classification before procuring regenerative tissue allografts. Sourcing from compliant distributors mitigates regulatory liability and protects clinical operations across specialty practices.

Understanding the Role of the FDA Tissue Reference Group (TRG)

The Tissue Reference Group (TRG) was established by the U.S. Food and Drug Administration (FDA) to provide a single reference point for jurisdiction and regulatory classification of HCT/Ps. Composed of representatives from the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH), the TRG evaluates specific medical tissue products to determine whether they fall under Section 361 or Section 351 of the Public Health Service (PHS) Act.

For medical practice managers procuring biologics, understanding TRG determinations is critical. Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, or spread of communicable diseases and do not require pre-market approval, provided they meet four key criteria:

1. The product is minimally manipulated.
2. The product is intended for homologous use only.
3. The manufacture does not involve combination with another article (with limited exceptions).
4. The product does not depend on metabolic activity of living cells for its primary function (or is for autologous use/allogeneic use in first- or second-degree blood relatives).

If a distributor offers tissue products that violate any of these conditions—such as marketing structural tissues like birth tissue for non-homologous systemic indications—the product may be reclassified as an unapproved biologic under Section 351. Practices that purchase and administer unapproved 351 products risk regulatory enforcement, product seizures, and professional liability. Conducting a structured audit of your distributor's compliance documentation is an essential operational safeguard.

FDA TRG Compliance Audit Checklist for Biologic Distributors

When evaluating existing or potential tissue distributors, medical practice administrators should utilize the following checklist to verify that supplier operations, sourcing, and documentation align with FDA guidelines and TRG determinations.

1. Regulatory Registration and Licensing

• FDA Establishment Registration: Verify that both the tissue processor and the distributor maintain active registration with the FDA as HCT/P establishments via the FDA Human Cell and Tissue Establishment Registration (HCTERS) database.
• State Tissue Bank Licensing: Confirm that the distributor holds required state-level licenses for wholesale drug or tissue distribution (e.g., Texas tissue distributor licensing).
• FDA Form 483 and Inspection History: Request written confirmation regarding recent FDA facility inspections, including any Form 483 observations or Warning Letters issued to the manufacturer or distributor within the past 36 months.

2. TRG Jurisdiction and Product Classification

• TRG Opinion / Regulatory Exemption Letters: Obtain copies of formal TRG inquiry responses or regulatory counsel letters establishing the specific Section 361 status for every allograft product line offered.
• Minimal Manipulation Verification: Ensure processing methods do not alter the original relevant characteristics of the utility tissue (e.g., micronization or chemical digestion that alters structural integrity).
• Homologous Use Marketing Alignment: Review vendor promotional literature, training materials, and representative statements to confirm that products are marketed strictly for intended homologous functions (e.g., cushioning, covering, or structural support for dermal or musculoskeletal defects).

3. Donor Eligibility and Safety Protocols

• Donor Screening Records: Confirm that all allografts originate from tissue procurement organizations adhering to 21 CFR 1271 Subpart C donor screening regulations, including comprehensive medical history reviews.
• Communicable Disease Testing: Verify that donor testing is conducted by CLIA-certified laboratories using FDA-licensed screening tests for HIV-1/2, Hepatitis B, Hepatitis C, Syphilis, and HTLV-I/II.
• Certificate of Analysis (CoA): Ensure a lot-specific CoA accompanies every product shipment, documenting donor eligibility, sterility testing results (USP <71>), and endotoxin testing (USP <85>).

4. Cold-Chain Management and Supply Chain Integrity

• Temperature Logging: Audit the distributor's storage and transit protocols to verify continuous temperature monitoring (e.g., liquid nitrogen phase, -80°C ultra-low freezer, or controlled ambient tracking).
• Validated Shipping Containers: Confirm that validated insulated shipping containers with calibrated temperature indicators are used for all clinical deliveries.
• Lot Traceability: Ensure the distributor maintains complete lot-tracking logs capable of tracing tissue from donor recovery through distributor handling down to the individual practice purchase order.

Operational vs. Clinical Perspectives on Vendor Compliance

Maintaining a compliant tissue procurement process requires alignment between a practice's administrative and clinical leaders. While both share the ultimate goal of patient safety, their operational focus differs.

Operational Priorities: Risk Management and Cost Efficiency

For practice managers and administrators, distributor compliance is primarily an exercise in risk mitigation and financial stability. Sourcing non-compliant HCT/Ps exposes the practice to commercial disruption, insurance claim rejections, and legal exposure. Operational leaders must focus on:

• Contractual Indemnification: Securing supply agreements that hold the distributor contractually liable for product compliance and regulatory claims.
• Cost-per-Treatment Transparency: Ensuring clear fee structures without hidden shipping, dry-ice surcharge, or storage fees that impact margin predictability.
• Audit Readiness: Maintaining a centralized repository of CoAs, tissue logs, and distributor licenses ready for state medical board or health department inspections.

Clinical Priorities: Product Efficacy and Processing Integrity

For medical directors and treating physicians, compliance directly impacts biological safety and patient outcomes. Clinical leaders evaluating distributors focus on:

• Structural Integrity: Confirming that processing methods preserve extracellular matrix (ECM) architecture without relying on illegal enzymatic digestion or unapproved cellular expansion.
• Sterility Assurances: Reviewing microbial control mechanisms (e.g., e-beam irradiation vs. aseptic processing) to ensure zero risk of pathogen transmission.
• Handling and Reconstitution Standards: Evaluating thawing, handling, and delivery protocols to ensure seamless clinical integration within existing procedure workflows.

What This Means for Your Practice: Concrete Action Steps

To transition compliance management from a reactive burden to a structured operational routine, practice administrators should execute four immediate actions:

1. Perform a Vendor Audit: Request updated regulatory files, FDA registration numbers, and sample Certificates of Analysis for every biologic supplier currently utilized by your practice.
2. Audit Past Tissue Logs: Cross-reference your practice's patient procedure logs against distributor lot tracking records to ensure 100% traceability for all injected or applied allografts.
3. Update Procurement Policies: Mandate that no new tissue product line be added to inventory without prior review of its TRG classification and manufacturer 361 compliance file by both the practice manager and clinical director.
4. Partner with Compliant Distributors: Work exclusively with established suppliers who maintain transparent compliance records, certified cold-chain logistics, and dedicated account support.

Maintaining Quality Assurance in Regenerative Practice

Navigating FDA regulations and TRG guidelines requires diligent vendor management. Sourcing high-quality human cells, tissues, and tissue-based products from established suppliers protects practice operations and ensures patient peace of mind.

At Dallas Regenerative Solutions, we provide compliant tissue allografts, regenerative devices, and practice support tailored for regenerative medicine doctors and healthcare administrators. Review our compliance standards and regulatory protocols on our FAQ page, or contact our team to request sample product documentation and schedule a vendor consultation.